Goldman Sachs upgrades BioNTech to Buy, highlighting the potential of its cancer drug BNT327 and forecasting strong future revenue amid shifting company focus.
Latest Ratings for BNTX
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Feb 2022 | HC Wainwright & Co. | Maintains | Buy | |
| Feb 2022 | Morgan Stanley | Maintains | Equal-Weight | |
| Feb 2022 | Redburn Partners | Upgrades | Sell | Neutral |
